AbbVie Other Products — Net revenues decreased by 6.5% to $617.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 18.0%, from $752.00M to $617.00M. Over 4 years (FY 2021 to FY 2025), Other Products — Net revenues shows relatively stable performance with a -0.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests successful monetization of secondary product lines or growth in non-core business areas, while a decrease may indicate the divestiture or natural decline of legacy products.
This metric represents the total net revenue generated by product lines or business activities that do not meet the quan...
Most large-cap pharmaceutical companies report similar 'Other' or 'All Other' segments, typically representing a small single-digit percentage of total corporate revenue.
abbv_segment_all_other_net_revenues| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $640.00M | $547.00M | $594.00M | $1.21B | $1.01B | $925.00M | $992.00M | $691.00M | $741.00M | $782.00M | $821.00M | $744.00M | $810.00M | $726.00M | $752.00M | $747.00M | $603.00M | $660.00M | $617.00M |
| QoQ Change | — | -14.5% | +8.6% | +103.9% | -16.7% | -8.3% | +7.2% | -30.3% | +7.2% | +5.5% | +5.0% | -9.4% | +8.9% | -10.4% | +3.6% | -0.7% | -19.3% | +9.5% | -6.5% |
| YoY Change | — | — | — | — | +57.7% | +69.1% | +67.0% | -42.9% | -26.6% | -15.5% | -17.2% | +7.7% | +9.3% | -7.2% | -8.4% | +0.4% | -25.6% | -9.1% | -18.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.